Regeneron cuts top end of eye drug sales forecast

(Reuters) – Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. The company’s shares fell 7.6 percent to $365 in premarket trading on Tuesday. Regeneron said it expected full-year 2014 sales of Eylea, its eye injection drug, within a range of $1.7 billion to $1.74 billion. The company, more accustomed to raising its Eylea sales forecasts, cut the range from $1.7 billion to $1.8 billion. …
Go to Source